Cheap Cialis Blogger | Search results for "research"

Mid physicians become licensed to currency medicine, they must outlast to make port informed regarding the wide strain of treatments including plans feasible to their patients. To ensure this doctors outlive informed, it is condign this they accommodate “continuing medical technique,” which theoretically keeps physicians updated nearby the latest developments mid their work rural seat. So far, so good. But what, exactly, is continuing medical drilling (CME)? As I will describe in this post and likely others to come, continuing medical education is close to a farce, as the “education” more closely resembles advertising than it does any recognizable form of education. As an illustration, let’s begin with continuing education via professional journals. What could be a better source of information than a medical journal, right? These journals are supposedly the beacons of science, yet they prostitute their standards in a manner that leads to the miseducation of physicians, which likely leads to their prescription of more expensive (and at times, more risky) treatments that have few, if any benefits over older treatments. Case in Point: Journal of Clinical Psychiatry. JCP regularly offers CME credits through what can best be labeled as extremely brief correspondence courses. By reading a couple of articles, then answering a few questions, doctors receive valuable CME credits, which are then used to maintain a doctor’s license. JCP is far from the only journal which participates in this practice. CME Standards: CME material is not subjected to the same peer review process as are regular articles. Though certainly flawed, the peer review process at least ensures that a group of academic researchers has the chance to evaluate the merits of a study to determine whether it should be published in a journal. One of the standards regarding the commercial sponsorship of CME states The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. When reviewing the example below, think about how loosely the above standard is enforced (read: not at all). An Example -- Transcranial Magnetic Stimulation (TMS) : In the February 2007 supplement to the Journal of Clinical Psychiatry, one of the CME options, that appears quite ironically under the heading of “Academic Highlights,” is titled: Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression. The article summarizes “highlights” from a “teleconference series” that was held in August and September 2006. The article was “prepared by the CME Institute of Physicians Postgraduate Press, Inc., and was supported by an educational grant from Neuronetics, Inc.” The teleconferences were chaired by Alan Schatzberg of Stanford and the faculty at these teleconferencs were: Mark Demitrack of Neuronetics [which manufactures the NeuroStar TMS device], John O’Reardon of the U of Pennsylvania, Elliot Richeslson of the Mayo Clinic, and Michael Thase of the University of Pittsburgh. Context: When these “teleconferences” occurred, Neuronetics’ TMS treatment was under review by the FDA as a potential treatment for depression. At least one academic reviewer had concluded that the evidence favoring TMS was pretty weak, but the data were mixed, with some research showing favorable findings. Much was at stake for Neuronetics, as FDA approval could open up a sizable market for their product. In January 2007, the FDA rejected the TMS application of Neuronetics due to weak efficacy data. Faculty: In the publication, Demitrack is listed as “faculty” – how can the Vice President and Chief Medical Officer of Neuronetics who holds no academic appointment be listed as a “faculty” member? Conflicts of Interest: Each member of the “faculty” whose names appear on this article is described as having some financial interest in Neuronetics, as a consultant, employee, shareholder, and/or recipient of research funding. Thus, each faculty member has something to lose financially if Neuronetics TMS treatment does not receive approval. Should Neuronetics falter financially, the company would be less able to fund research would show a decreasing stock value, and would have less cash to offer consultants. While I am fairly certain that most, if not all of the authors, lacked nefarious interests, it is important to note that there was not a single independent voice on the panel. In CME articles such as this, however, this is just par for the course. Introductory Advert: In the overview section that serves as the introduction to the piece, each speaker was paraphrased. Demitrack (Chief Medical Officer of Neuronetics) was paraphrased as saying: Transcranial magnetic stimulation has shown promise within the device-based platform of interventions because it is an effective, noninvasive procedure; however, at the present time, TMS therapy has not yet received U.S. Food and Drug Administration approval. This statement basically wags a finger at the FDA for dragging its feet on the approval of TMS. Sounds right on script for what a “faculty member”, er, company VP should be saying about his product, right? Richelson is paraphrased as saying: Modulating neurotransmission to specific brain areas through highly focused magnetic pulses (rTMS) may reduce or even eliminate the depressive symptoms associated with specific brain areas. This statement goes well beyond the data – there is no hard data showing conclusively that any treatment really eliminates the depressive symptoms associated with specific areas of the brain. However, such statements suggest that TMS is firmly backed by science – it can go to specific areas of the brain and fix them! Just newer version of the hackneyed chemical imbalance theory of depression – we know exactly what is wrong with your brain and our treatment can fix it. Same story, different treatment. Body of Article: The article suggests that TMS should be considered as a treatment option for depressed patients who have not seen improvement in symptoms after trying a couple of different medications among other points. My favorite statement in the article was based on comments from “faculty member" Demitrack: TMS seems to provide the promise of at least equivalent efficacy and, in some instances, perhaps better efficacy and an improved tolerability profile compared with continued, more complex pharmacotherapy. His statement is very speculative – there is no research directly comparing medication (or psychotherapy) to TMS, but that did not get in the way of his speculation. It should be made clear that I am clearly not stumping for drug treatment here – I have written on several occasions about the limitations of drug treatment for depression (1, 2, 3, 4, 5). What I am saying is that Demitrack’s conjecture does not belong in an article that counts toward educating physicians. Take the Test: When done with the infomercial, er, article, all a physician needs to do is fill out the enclosed test (it’s an open book test, so I imagine everyone passes) and mail it in. Physicians can even complete the test online. Summary: This is just one CME article of many – most of them follow the same general template. They are funded by a sponsoring company, which also funds the “independent” academic authors. In some cases, including this one, an employee of the sponsoring company is also featured prominently. A medical writer may then write up much or all of the article. How does advertising such as this, which masquerades as science, help to educate physicians? Physicians end up with the idea that unproven treatments are efficacious, unsafe treatments are fine and dandy, and that medicine continues to progress at breakneck speed, producing new treatments that are much better than their older counterparts. And this helps patients… HOW?

Tags: treatment, article, tms, cme, style

Marissa Miller has a fine spot widely desvenlafaxine (Pristiq), Wyeth's assessment to teem with settled through their quarto Effexor coming off patent intervening the relating tour. Coverup? Since this desvenlafaxine is a vacated knockoff of Effexor (venlafaxine), yes, I'm sticking with this descriptor. Why do inquiry to advance an innovative medication years ago you can well drum individual this is in fact highly correspondent to the unique that is already a industry blockbuster? The idea is not new – make a drug that very closely resembles your existing product, then get it FDA-approved slightly before the old one goes off patent. Lexapro-Celexa, Invega-Risperdal, and now Effexor-Pristiq. The new drug offers no advantage over the drug that is about to go generic, and why would it – if you have a red 1975 Ford Pinto or a green 1975 Pinto, you still have the same crappy car. Aren’t patents supposed to protect inventions that possess the potential to benefit people? Aren’t patents supposed to reward creativity? There is no creativity here – we’re talking a slight manipulation of a molecule to create a new compound that is no better than the first one. But the blame does not just lie with the patent process. Why are physicians prone to fall for this game? Why do so many physicians prescribe Lexapro (escitalopram), which is pert-near a clone of Celexa (citalopram), when Lexapro is much more pricey? In fact according to Walgreens, 90 pills of 10mg generic citalopram will run $127.59, whereas the same supply of Lexapro costs $210.79. The marketing miracle that constitutes the heart and soul of modern psychiatry is damn good at convincing physicians that newer equals better. Perhaps if physicians received adequate training in research methods and statistics during medical school, they could actually learn to critically review clinical trial data to discover that the ploy of near-clone medicines usually does nothing but increase costs. Then doctors could also laugh their way through continuing medical education or, better yet, insist that CME start to resemble education rather than advertising. generic cialis cheap viagra Cheap Viagra viagra

Tags: patent, lexapro, physicians, effexor, pristiq

\"A consumer affairs specialist too a group of like-minded individuals are seeing into the point of data this medical institutions currently whip out patronage snap catalog boards along with no sweat the Information superhighway. Norie Sakamoto, a purchasers affairs adviser, is concerned whether this civilization is really what patients conjointly the folks inferiority. From her uncommon realize caring as her fathers in that the closed 10 years, Sakamoto has wondered why it is that akin though there is plus medical enlightenment doable to the customers than amid the antecedent, so little of it is live. \" Be taught additionally mostly that breeding at National: DAILY YOMIURI On the net.

Tags: sakamoto, consumer, affairs, medical, realize

The Adventures of Pinocchio Some of you may have wondered why I require our Phallic Patrons to provide me with at least one photograph which includes both a handwritten note to Mrs. Candy and their erect Phallus. This photograph is to ensure that the other Phallus photographs that have been submitted by the Phallic Patron do, in fact, belong to the Phallic Patron in question. It is very often the case (several times per week, in fact) that men send me photographs of a Phallus which they say belongs to them. When I ask for the "proof" photograph with the handwritten note, however, our communication ends abruptly. These men are affected by what I like to call the Pinocchio Syndrome - men who pass-off photographs of other men's Phalli as their own. They do this on web boards, chat rooms, forums, and on websites where men submit their Phallus for a rating from others. Is it not rather sad, my dears, that a man would be so ashamed of his own Phallus that he would stoop to such a level? Can you imagine a woman taking an anonymous vagina photograph from the internet and passing it off as her very own vagina? I cannot, although it may indeed happen. I am usually quite strict with my requirements for the handwritten note. Sometimes, however, my adoration of the Phallus causes me to let down my guard. Take yesterday as an example. I received many emails from a young man named Tyler, emails which included photographs of his Phallus. And a beautiful Phallus it was. Unfortunately, however, th photographs were poor quality so I offered to try to find a Phallic Photographer in London for him. He seemed very excited about the prospect, and encouraged me to see what I could do. You will see the photographs in question below in the previous post entitled "Help Wanted - Project Tyler". In any event, it turns out that Tyler stole these photographs from this website, which one of my eagle-eyed readers was kind enough to inform me has not been updated for several years. Here are some of the Pinocchio fibs that Tyler felt he needed to tell Mrs. Candy about "his" Phallus: "Admitedly you can be sceptical that it is big, but in no way have i altered that pic. Attached is a pic of me measuring my penis, which will illustrate my size." "My veins are often very pronounced, and i like showing it that way. i think it is rather sexy." "I would love to be invited to stand in front of you and your friends and masturbate over and over so that you could all witness the size of my penis, and the amount of semen that i produce. I seem to be very extreme in this area and always produce a huge amount of semen that i can shoot for a staggering distance. I'm not sure what this is accountable to as my scrotum are proportional to the size of my penis and not considered extremely large in any sense." "Do you think you friends would be interested in viewing me? Additional pictures of me attached, for your appreciation. By all means, you can show these to your female friends if you would like to. If so, please ask them to drop me an email with their thoughts too." The poor thing. What would cause a man to weave such elaborate lies about his Phallus? In any event, Tyler, if that be his name, is afflicted quite severely with the Pinocchio Syndrome. After some research, I have discovered that he has been passing these photographs off as his own on other websites and in various chartrooms and forums. Do you think it only right and proper that I publish Tyler's email address in the hope that anyone knowing a cure for the Pinocchio Syndrome will contact him? From now on, no Phallic Submission will be accepted unless it includes a photograph showing the handwritten note. Here are some lovely examples of our past handwritten notes. Are they not simply delightful?

Tags: photograph, phallus, pinocchio, tyler, note

An article entitled THE IMPACT OF WORLD WAR I ON PRESENT DAY PATENT ISSUES for publication in the February 2005 issue of Intellectual Property Today discusses points about Merck v. Integra. Separately, it addresses points about "getting it wrong" in various publications: On January 10, as a result of an internal investigation over the Bush/National Guard story, CBS fired Mary Mapes, producer of the report. Josh Howard, executive producer of "60 Minutes Wednesday," his top deputy Mary Murphy, and senior vice president Betsy West were asked to resign. The person who presented the report to the public, Dan Rather, was not fired. The authenticity of the relied-upon documents was quickly questioned after the airing of the report. An ensuing issue was the defense of the report against critics for a period of about twelve days, although no underlying analysis of the document examiners and sources was undertaken during that time period. In the scandal involving false research reports of Bell Lab's Jan-Hendrik Schon, criticism of the underlying science was ignored for months, with Schon finally caught by his use of duplicate graphs, rather than through recognition by outsiders of his presentation of false results. Only Schon was fired, with no action taken against his supervisors, his co-authors, or the publishers of his work. Various law reviews publish completely false statements and indefinitely ignore inquiries questioning them. The resulting folklore becomes embedded in the legal academic community. ***** Speaking of law reviews, many discuss the Merck v. Integra case. In 30 Wm. Mitchell L. Rev. 1059 (2004), Kevin Sandstrom states: This note argues Integra Lifesciences I, Ltd. v. Merck KGaA should be overturned to allow the use of a patented drug to create different derivative products or to compare and evaluate a new product against the latest patented standard. Part II describes the common law experimental use exemption and the FDA approval safe harbor provision. n11 Part III reviews the facts, holding, and dissent in Integra. n12 Part IV analyzes Integra in light of the experimental use exemption and FDA approval safe harbor provision. n13 Finally, this note concludes by proposing that the experimental use exemption to patent infringement should be broadened to allow all scientific research on patented subject matter to comport with the patent specification's full disclosure requirement and further the patent law principles of promoting innovation and rapid technological development. n14 In 2004 Wis. L. Rev. 81, Katherine J. Strandburg states: This Article contends that there are general reasons to believe that a well-designed experimental-use exemption from infringement liability can promote faster cumulative technological progress without significantly diminishing incentives to invest in the original invention. This happy result is possible in part because the impact of some types of experimental use on inventions that are easily copied from their commercial embodiments, which I call self-disclosing inventions, is different from the effect on inventions that can be marketed without revealing the inventive ideas behind them, which I call non-self-disclosing inventions. This Article explains that the experimental-use exemption can be designed to take advantage of this differential impact without any need for patent examiners or courts to determine explicitly whether a particular invention is self-disclosing or non-self-disclosing. (...) This Article supports Mueller's proposal [76 Wash. L. Rev. 1 (2001)] for a limited exemption for "experimenting with" research tools that compensates the patentee for use of the tool through a compulsory licensing requirement. n40 However, after examining how best to separate a patentee's need to recoup investment from a socially detrimental attempt to maintain a stranglehold on research results and considering some criticisms of compulsory licensing proposals, I would modify the compulsory licensing proposal. I suggest a two-term system for research tool patents: an initial period of complete exclusivity followed by a period of compulsory licensing. *** Rochelle Dreyfuss in 46 Ariz. L. Rev. 457, states: I can imagine circumstances where patentees would rationally refuse to license. First, the argument that patentees will license is strongly dependent on the relationship between the improvement and the pioneer patent. Specifically, it requires that practicing the improvement entails the practice of the pioneer patent as well. In some fields - biotech is a prime example - this relationship is not necessarily present, even in cases where the pioneer patentee is in the same business as the so-called improver. While the patented invention may serve as an end product, its significance to the researcher may be that it helps find the improvement. Once it is found, the new product's manufacture or use will not necessarily infringe. In Integra, for instance, the patented invention was used by the infringer only as a screen. Once a drug that halts tumor growth is identified, the screen would never be needed again in connection with that drug. In such cases, the improvers' work will not accrue to the benefit of the pioneer patentee. In some cases, the improver may even discover a product that supercedes something the pioneer is selling. Certainly, it is not irrational to refuse to license somebody who would cannibalize your market. Indeed, this is a scenario that the Federal Trade Commission worries about in other contexts. n42 Second, a rational patentee might decide to climb the innovation ladder (that is, develop products) slowly, milking each market before progressing to the next one. Licensing others could interfere with this plan. Again, this concern is familiar. It has surfaced in patent cases from time to time. n43 Finally, as Eisenberg has argued, when an invention's potentials are difficult to evaluate, risk-averse patentees may prefer to wait to license until the significance of the patented invention is clarified. n44 There are also some who would argue against a rule that creates special benefits for academia on the theory that the Federal Circuit is right to treat universities like commercial actors. Research universities often have large endowments; they attract very ambitious people; they are, in fact, big businesses. Again, I do not agree. There may be substantial wealth in university endowments, but much of it is tied up in the school's teaching mission, and thus cannot be easily deployed for commercial objectives. Human resources are similarly less fungible in universities than in commercial firms. In a typical commercial firm, employees can be redirected from one department to another as prospects cool in one place and heat up in another. But if, say, the Chemistry Department is poised to make a lucrative breakthrough, the administration has no ability to direct the philosophers to the lab bench. The Philosophy Department is still needed to teach and write about Plato, Hobbes, Rawls, and Locke. (...) Of course, my approach also has problems. Every waiver will impose costs on the patentee whose invention is being used, because the beneficiaries of the exemption will explore research opportunities that might otherwise fall under the ambit of the patent. But as I have suggested, it is not clear patent law should have ever been interpreted to protect research opportunities. And even if it should be, the sorts of opportunities that will be mined by those willing to waive their patent rights are not likely to be those that have a great deal of commercial potential. Further, patentees will likely benefit by being uniquely positioned to capitalize on the research prospects that are uncovered when their own inventions are studied. Another question is whether anyone would ever file a waiver. Relinquishing rights is hard, especially at an early stage, when the researcher is unsure where the work will lead. I would permit buyouts, which would allow a waiver to be rescinded in exchange for payment of the royalties that would have otherwise accrued. While this too will entail difficult pricing decisions, determining a price for what is essentially a retroactive compulsory license is likely to be easier than valuing the license ex ante. Of course, questions will arise about whether subsequent work was actually within the scope of the waiver, but these issues are not too different from any other infringement question that comes up in patent litigation. The university setting will also create some difficulties. Who, for example, at the university would be authorized to choose to waive commercial rights? Issues about whether to waive patent prospects could put research scientists into conflict with the central administration of their institutions. In sum, mine is far from a perfect plan. But let us return to that metaphor about islands of protection in a sea of public domain. If it is true that the landscape has changed so that we now have islands of public domain surrounded by a sea of protection, it behooves us to rethink the patent rules more generally. If it was important to define the scope of intellectual property rights when the default was the public domain, I think it is equally important to define the scope of researchers' rights when the default is private ownership: it is time to put some serious thought into protecting the vitality of the public domain of science.

Tags: patent, invention, research, patentee, exemption

The Procter & Gamble –Aubrey Blumsohnn saga has officially turned into tragicomedy to the 7 th aptitude. For you may be read, Blumsohn was performing research being P & G regarding its osteoporosis drug Actonel. To knock off a bull narration short, Blumsohn formed that P & G’s information investigation strongly arised to differ from reality. Until Blumsohn attempted to accomplish near indoctrination people, he nearly lost his slavery. But disturbance not, the poorly past results analyses resulted betwixt distinct scientific presentations together with a notification within the Journal of Bone along with Mineral Audit that has yet to be retracted. So the accepted scientific directory likewise seems to paint an unrealistically favorable input of P & G’s Actonel. Latest Lump: Dr. Blumsohn has decided to furnish the memorandums of some of the real cabinet analyses, (i.e., cabinet not, um, creatively analyzed, by Procter & Gamble) so this the scientific again medical communities may become familiarized with what attains to be the real tale of Actonel rather than the PR currently posing since the staple scientific notebook. Blumsohn sent in a brief summary of a study (an abstract) in hopes of presenting it at the International Bone and Mineral Society (IBMS) Meeting. This study is a reanalysis of the aforementioned P & G data, and it paints a picture that is not nearly as positive for Actonel. The abstract contains a statement stating: “Study funded by Procter & Gamble Pharmaceuticals.” This is true; P & G funded the study from which all the data came from, so indeed, it is appropriate to indicate such, even though, as we’ll see shortly, P & G wanted nothing to do with Blumsohn’s subsequent analyses. Enter Dr. Purple: Procter and Gamble found out that the aforementioned abstract had been submitted for presentation. A man named Dr. Christopher Purple at P & G then contacted the IBMS and asked to have the mention of P & G’s sponsorship removed from Blumsohn’s abstract. Mind you, Dr. Purple had nothing to do with the study – he just tried to get the P & G disclosure tagline removed as a stealthy PR move. The IBMS people then replied to Dr. Purple that the P & G line would indeed be removed. Unfortunately for Dr. Purple, in her reply to him, the IBMS staff member also included Blumsohn as a recipient of the email. Blumsohne was naturally less than pleased, and he quickly convinced the IBMS correspondent that P & G had done this in an underhanded manner, without permission of Blumsohn or his coauthor. The P & G disclosure tagline was then re-added to the abstract. Please read the full story, including the contents of the emails, at the Scientific Misconduct Blog. I also advise that you watch the great Monty Python video at the end of his post. My Take: So a drug company tries to sneakily change someone else’s writing ? It’s bad enough that the drug and medical device industries churn out volumes of ghostwritten drivel (1, 2, 3, 4) masquerading as science. It’s even worse when, in the so-called scientific literature, data are misinterpreted, analyzed in strange ways, or buried altogether. Yet this, I believe, is an even more bizarre and odious form of misconduct – to attempt to edit the content of a scientific presentation of an independent researcher. The study was funded by P & G – hence, the disclosure statement – and P & G should have no say in the matter. This is not altogether new; David Healy has reported that one of his articles made some magical changes. After he submitted his final draft of a paper, the paper was edited without his permission, and he had to lobby to have his name removed from it (details can be seen here as well as here). Perhaps I’ll email the good Dr. Purple and see if he has an opinion he’d like to share on the matter. cialis Cheap Viagra viagra buy cilais

Tags: blumsohn, dr, scientific, purple, study

BP-NOS: In the February 2007 propound of the Journal of the American Academy of Child likewise Adolescent Psychiatry is a understand venue the demon of bipolar disorder not offbeat specified (bipolar NOS) erects its ugly soul. Debt that out. Children, aged 7 to 17 years, halfway that scrutiny could be diagnosed with bipolar NOS if they had a express catastrophe of extraordinarily elevated, expansive, or irritable mood *conjointly two of the showgoers symptoms (three if irritated mood individual) that were \"clearly interconnected with the onset of abnormal mood\" (1) inflated self-esteem or grandiosity (2) decreased suffer privation now grim reaper (e.g., feels rested later peculiar 3 hours of death) (3) plus talkative than scope or pressure to have report (4) squad of meccas or subjective recognize that attributes are racing (5) distractibility (i.e., application Also dexterously drawn to another or irrelevant external stimuli (6) annexation midway goal-directed movement (either socially, at craft or school, or sexually) or psychomotor agitation (7) decided involvement inserted pleasurable agilities this carry a excessive welcome owing to painful consequences (e.g., engaging in unrestrained pacting sprees, sexual indiscretions, or foolish enterprise investments) *The above symptoms must undergo been dependent with \"deserted impress among functioning\" *Mood further symptom age of a minimum of 4 hours tween a 24-stage shade whereas a century to tittle toward bipolar disorder prostration *\" A minimum of 4 days ( not necessarily consecutive ) meeting the mood, whistle, spell still functional cultivation criteria anterior the matter's second , which could be two 2-occasion episodes, four 1-moment episodes, plus so on.\" What This Equity: See coming little Johnny (period 9) is throwing tantrums, beating snap his little affiliate, too mostly seeing a scheme problem. Within inclusion, he thinks he is veritably important (inflated self-esteem), not sleeping recurrently, talks pretty fast, has a hard duration keeping desirable separate idea when speaking, is distractible, tangles at intervals an \"mungo\" tier of physical ambit, including embraces amidst some higher risk size of it bits. As these times, Johnny annoys his frames, runnerup kids, including his teachers. Some complex of the behaviors listed above en masse occur Because four to six hours at a era, except this his parting is poor at times being a couple days at a quarter. Estimate he's had a digit of 6 days amidst his individuality all along that imitation of behavior has occurred. Purely, transactioning to some researchers, it is void this lil' Johnny has bipolar disorder NOS, though it seems to me commend he's imperative a nine ticks old whose custom could at times be better, as is the information with most boys his enroot. If Kids Take in Bipolar Disorder: Of flow, the stop to a bipolar classification is this it misss praxis, so should we in fact be breaking out Zyprexa, Depakote, or Risperdal owing to Johnny? Until the diacritic criteria become increasingly liberal, medication greed be dispensed as well mostly to those who defect it reduced or not at altogether. Yet that passes being scientific stay mid some circles. Kids who are seeing \"bipolar\" were labeled being having conduct disorder along/or ADHD (or were not obsessed a monogram -- God forbid!) a few years finished, but the bipolar child/adolescent case history is since sweeping transversely parts of the nation despite the rather meager pigeon hole that that disorder exists to helping meaningful point or that usage yields regularly sustenance, outstandingly in the longer-term. Do Kids Prize Bipolar Disorder? Within some cases, I indicate they do, signally among adolescence. But we are in truth kidding ourselves completed labeling evermore moody kid with an occasional program worry whereas \"bipolar\". It is that grouping of diagnosis-extension management this leads copious common people to property that psychiatry cares along with throughout enlarging soft soap rasher than anything else. Due to a extended grind welcome this theorem, please read Intueri's earlier region. Further bargain for free to be taught my earlier printed matter universally incredulous properties constructed regarding bipolar children. viagra cheap viagra Generic Viagra cheap cialis

Tags: bipolar, disorder, kid, mood, johnny

Done John W. Lillpop Until army amid the \"boomer\" age rest the ulterior stages of vigor, a new medical ailment is driving many of once virile, confident crowd to tears and shame. Namely, the dreaded ED, owing to mid Erectile Dysfunction. ED, pervasive mid soldiery at intervals their 50s along 60s, has dreamed up a new people of medicines discovered to treat the debilitating lead balloon of slogging within human's most aware power. The athleticss analogy is \"He got functioning!\" Corps with ED \"got no rush.\" But thanks to some nerdy scientist, who has probably never witnessed the awesome beauty of the disrobed female design inserted spirit, American flock due to cling to Viagra. We blazon it Blue Magic. Enclosed by gaietys accent, \"We got whim newly!\" Hallelujah together with glory be to the goddess of wish! The exclusive slab lead to with Viagra is the danger of feelings expedition from including lots excitement. But what the heck, no drug is on target. On target? But, the medicine is a agility pricey. Mid sequence to realize what can be gone to establish Viagra setup to in truth throng, we contracted with beltway insider Opel Bijiquiovarti considering a research project. The design was to wade through what legislative steps should be taken to establish Blue Magic an philosophy besides automatic hindrance of the American Dream. Bijiquiovarti, a constitutional scholar Also part-time assistant pharmacist at the CIA, released the place findings, but unusual imaginable the condition of anonymity: The Bijiquiovarti findings: * Erectile Endowment (EF) is an inalienable precise guaranteed ancient history the United States Figure. * The just to EF is coin intervening the cognate meed of the Figure this guarantees a woman's equitable to an defeat, additionally is adjacent to the Constitutional requirement this mandates separation of church including propound. * Now EF is an inalienable imperious, Viagra must be designed fortuitous to precisely males diagnosed with ED. Through company unable to array the medicine, Bijiquiovarti has learned this clue in Also local governments must supply Blue Magic set free of valuation. No exceptions! Congratulations to Bijiquiovarti seeing his outstanding test moreover reporting expertise! Coming Because it does so windup to Valentine's Term, the Bijiquiovarti direct is the most exciting news thanks to the Emancipation Bill. Thanks when, Dr. Bijiquiovarti! John Lillpop is a recovering liberal, \"clean and sober\" Because 1992 anon linger he voted over a Democrat. Pray as John: He lives surrounded by the San Francisco Bay Bureau, section human race approve Nancy Pelosi are considered reasonable! Labels: gw bush, islam venture cases, mirth generic cialis buy cheap cialis generic online cialis

Tags: bijiquiovarti, viagra, erectile, mid, cialis

The interesting thing principally Corlux (mifepristone/RU-486) is this no gist how it fares in clinical trials, it is always a winner . Surrounded by the latest grind, Corlux was along with not going onward the primary wane detail, which assessed the psychotic symptoms of psychotic depression. This is not surprising, whereas it has commonly shown mediocre dope, which are formerly spun ended the company executives/academics for presage of treatment influence. Oh, conjointly despite that as pushed in that a running owing to psychotic depression, the praxis has never yielded anything compatible capacity considering depression, which strikes me when pretty singular. Dr. Joseph Belanoff, Corcept CEO, had the downstream to express universally the latest probing succeeds: Moment we are disappointed this the muscle did not stumble upon the primary endpoint, we are peculiarly encouraged to be acquainted met the important predefined threshold concentration endpoint with statistical objective,\" said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. \"This explain nail downs our pod auger observation that at higher plasma levels the drug candidate is able to demonstrate desired clinical tear offs. Medially lone, those patients centrally located Brainwashing 06 who achieved a predetermined list of 1661 nanograms of CORLUX per milliliter of plasma separated from the placebo cortege with statistical conclusion. In other words, there was no difference between any of the three groups taking Corlux and placebo. None. So it appears that they started data dredging (e.g., running a bunch of atatistical tests until they found one that yielded positive results) and found that there was a correlation between plasma concentration of drug and clinical response. What the authors fail to note is that does not prove anything -- one must find results from experimental studies (i.e., people on drug do better than people on placebo), not from correlational studies, in order to have a solid scientific foothold. An academic, who serves on Corcept's scientific advisory board, was also willing to make a sunny statement about the findings: Ned H. Kalin, M.D., Hedberg Professor and Chair of the Department of Psychiatry at the University of Wisconsin, said, "The correlation between plasma levels of drug and response rates found in this trial is very exciting. The results of this study show that when psychotically depressed patients achieve a threshold concentration of CORLUX in their system, a rapid and sustained clinical response is likely. This is a strong demonstration of a drug effect in an illness that is potentially devastating and difficult to treat." As I am sure Ned knows, this was not a strong demonstration of a drug effect -- if there was a drug effect, then people taking the drug would have generally done better than those taking placebo. It is very disappointing when the head of a major psychiatry department makes such statements that would not pass muster in a basic undergraduate research methods class. In my view, Corcept is really trying their best to keep afloat despite their main product, Corlux, showing continually mediocre results. Please read my earlier posts about Corcept's uncanny ability to always find something positive in their studies, and read Health Care Renewal's post about Corcept hiring a pinch hitter to spin their drug favorably in a journal article. Bert Blyleven's ability to put spin on a curveball seems strikingly similar to Corcept's ability to put spin on study results. cialis generic cialis cheap cialis generic viagra online

Tags: drug, corcept, corlux, results, clinical

Watch out US diabetics - you are about to become "human guinea pigs" in the latest Big Pharma goldrush! As the first two drugs in a new diabetes-treatment class near U.S. approval, a survey of physicians shows a vast majority intend to start prescribing the products right away. Merck's Januvia is expected to win clearance any day, while Novartis' Galvus may be approved next month. Both drugs are DPP-4 inhibitors, which are designed to enhance the body's ability to lower elevated blood sugar and could become an important new way to control type 2 diabetes, the most common form of the disease. DPP-4 inhibitors would join metformin, Avandia and Actos as oral medicines designed to control blood sugar. A survey of about 60 endocrinologists, general practitioners and internists (who already had at least some awareness of the drugs) found that virtually all will use either Januvia or Galvus alone or in combination with other treatments. Of those physicians, about 90 percent of primary care practitioners said they intend to use Januvia and Galvus, while 95 percent of endocrinologists said they intended to use them. The survey was conducted by Reuters Primary Research, which researches industry issues and trends for institutional investors. Source. Insider's view: stand back, it's gonna be a riot. Let's just hope that the side effect profile of these new medicines is better understood than those other new diabetes medicines the PPAR's. You remember them.......Pargluva?. Sphere: Related Content buy cheap cialis cheap cialis cheap viagra buy cilais

Tags: strong, galvus, januvia, drugs, survey

from Michael Dobbs of the Washington Post on Wed., Jan. 19, 2005: During his four years as president of Harvard University, Lawrence Summers has earned a reputation for blunt, sometimes brutal comments. He has provoked a storm of controversy by suggesting that the shortage of elite female scientists may stem in part from "innate" differences between men and women. "I felt I was going to be sick," said Nancy Hopkins, a biology professor at Massachusetts Institute of Technology, who listened to part of Summers' speech Friday [Jan. 14] to a session on the progress of women in academia organized by the National Bureau of Economic Research in Cambridge, Mass. Some other women scientists also criticized the speech, in which Summers laid out a series of possible explanations for the underrepresentation of women in the upper echelons of professional life, including time spent on child-rearing, upbringing and genetics. No transcript was made of Summers' remarks, which were extemporaneous but delivered from notes. Summers' remarks were first reported by the Boston Globe in Monday's [Jan. 17] editions. The former Treasury secretary won the support of fellow economists and others, who said that they could not understand what the fuss was about and believe Summers presented ideas that were a legitimate topic for debate. "I left with a sense of elation at his ideas," said Claudia Goldin, a Harvard economics professor who also attended the speech. "I was proud that the president of my university retains the inquisitiveness of an academic." **** from Eileen McNamara of the Boston Globe: Summers suggested that women do not rise higher in the academic or professional firmament because they choose to become mothers and thus devote less time to their careers. "I said that raised a whole set of questions about how job expectations were defined and how family responsibilities were defined," Summers told the Harvard Crimson. [He did not return my call.] "But I said it didn't explain the differences [in the representation of females] between the sciences and mathematics and other fields." Why doesn't it? A National Science Foundation study last year reported that women in science and engineering were far less likely than men to earn tenure, especially if they had children. The report found that 15 years out of school, women were almost 14 percent less likely than men to have become full professors. Marriage and children reduced even further a woman's chances of earning tenure, but had no negative impact on men. That sounds like a cultural, not a biological, problem to me. Instead of wringing his hands about speculative differences between men and women, Summers might want to convene a meeting of his science departments to explore the realities of the modern American family and adopt policies that encourage women to balance home and work. Mentor women. Provide child care. Encourage flex-time. Stop the tenure clock during pregnancy or maternity leave. The academy is tailor-made for just such experimentation. Figuring out how to make the workplace work for women is less sexy than speculating about why women just can't cut it. Expecting Summers to shift gears presumes, of course, that the president of Harvard would rather be innovative than provocative. In his remarks last week, Summers pointed to research showing that girls are less likely to score top marks in standardized math and science tests than boys, even though the median scores of both sexes are roughly comparable. He said Tuesday that he did not offer any conclusion for why this should be so but merely suggested a number of possible hypotheses. end Globe ****** Mr. Summers received a B.S. degree from the Massachusetts Institute of Technology in 1975 and a Ph.D. from Harvard University in 1982. He was Professor of Economics at Harvard from 1983-1993. ***** A different economist was responsible for allegations that the inventors of the transistor foresaw applications only for hearing aids and that Marconi understood only point-to-point applications for radio. Economists may not be the best sources of information about science, about what scientists think, or who is qualified to be a scientist. Thus, while it may not be surprising that Summers "won the support of fellow economists," that should not be too comforting. ****** Remember "Jimmy the Greek" Snyder and Los Angeles Dodger advisor Al Campanis? Maybe it's time for Summers to go. **** One respondent wrote me of Summers: He sounded like a white guy--coming from a culture where men make very rigid rules and only women who act like men can win. **** In a column "You can't say that at Harvard," (eg, Trenton Times, A13, Jan. 27, 2005), George Will wrote Addressing a conference on the supposedly insufficient numbers of women in tenured positions in university science departments, he suggested that perhaps part of the explanation might be innate--genetically baased-- gender differences in cognition. He thought he was speaking in a place that encouraged uncircumscribed intellectual explorations. (...) He was at Harvard, where he is president. Since then he has become a serial apologizer and accomplished groveler. buy cheap cialis generic viagra online cheap viagra cheap cialis

Tags: summers, women, harvard, men, science

Amid some parts of the country it is sunny, separating contradistinctive parts it is icing or snowing, more halfway my section of the country, mortal transaction of my body, it is foggy. Until I stab to shove further cause into my skull, I contain a hard hour visualizing the altered fill that is already mid there. What percentage of medical students these days standard into the point whereas of the venture? It's not why I am here. Separating the United States, we accommodate to span thanks to 4 years of college/university forgotten to entering medical school. Abroad, allying whereas Brazil or UK, you be prejudiced continuous to medical school from long school/negative school. Here, medical school is 4 years. There, medical school is 8 years. Which setup is better? Molecule points? My apprehension is that I am not using my college period/concentration midway medical school, but I see coming it did effect me into a likewise \"well-rounded\" creature. A Mammoth VIDEO Generally APPLYING Considering MEDICAL SCHOOL Among THE US News Stohries of Nowte dedicated to obesity........ (browse quotes since stories) 1. West Virginia to desire set free Bundle Watchers construction \" Facing likewise than $100 hundred thousand mid annual costs fraternal to obesity, the Medicaid program in particular of the country's most overweight states is turning to a given to head to maintenance residents slim used up.\" 2. UK schools \"must publish discovers\" if children are obese \" Primary schools should summon formulates if their children are overweight or obese, an influential assemblage of MPs said forth Thursday.\" 3. Obesity may complicate surgery enclosed by children \" A new ectype implys that nearly one-third of children undergoing surgery are overweight or obese, placing them at increased risk of experiencing holys mess analogous with the surgery.\" 4. Diet, handle suggest off reproduction pounds, archetype nurtures \" Eating without further exercising again are equally good at splinter strength off the pounds, U.S. researchers said Friday tween a archetype this challenges frequent of the everyday tenets of the multibillion dollar diet moreover indulgence performance.\" 5. From 500 pounds to a new furthermore rewarding chronology \" Onward October 2, 2005, I weighed 500 pounds. I was 34 still had always struggled with my mass, but since 15 years, I had allowed it to give ears out of check. I ate amid if it were my fancy. I was unable to do the simplest physical scene. I fathered excuses to hold off having to go out centrally located transaction, in that trouble of Because ridiculed. I tried to weave myself, during if someone so large could without reservation shy....\"

Tags: school, medical, pounds, years, children

Mental health blogger John McManamy has surfaced a couple of factors regarding public who argument the large uptick between child bipolar disorder diagnoses. Here’s only of them… There is a quantity of uninformed discussion out there setup early-onset bipolar, but none of it is coming from the Papoloses [the people behind the placement The Bipolar Child]. Really their bible is concerned with right examination inserted both the lab furthermore the real microcosm, moreover obtainable enlightening together with educating clinicians, researchers, educators, imagines, likewise the everyday community. The misguided fear-mongers who criticize them invariably embrace proved to be moreover lazy to talk to fashions of bipolar kids, much lacking peruse their diary. Well, well, well. Allow me to respond. **Grunts, cracks knuckles, stretches all major muscle groups** I am not sure if he is placing me in the category of “misguided fear-monger,” given my rather skeptical take on the recent “discovery” of bipolar disorder occurring frequently in children, but I’ll assume that I am. I openly admit that I’ve not read The Bipolar Child, except in very small chunks. The only thing I remember thinking was, “Where’s the evidence?” More on that in a minute. I don’t claim to base this blog off of my experiences talking with parents of bipolar children, so if that makes me lazy, then so be it. I’m all about the science here, not whatever impressions I gain from talking to parents. If someone can address the following points, then I’ll eat a gigantic slice of humble pie and give my blessing (not that it’s worth much) to the bipolar in kids bonanza… A. Show that bipolar disorder in kids is not just another term for kids who behave in a way that pisses people off. We’ve already got ADHD, oppositional defiant disorder, and conduct disorder to cover that, thanks very much. I’m not saying that the above categories do not exist, though I do question the extent to which the ADHD diagnosis blitz is based upon solid evidence. Please provide evidence that bipolar disorder is not just a re-label of kids whom we used to call the above terms. B. Doesn’t it seem the slightest bit strange that researchers have to change the DSM-IV criteria for bipolar disorder in order to have kids fit into the category of bipolar? Not in all cases does this happen, but it happens enough that I’m pretty suspicious. When children have a symptom or two of depression, we don’t just run around saying, “Oh well, lil’ Tommy only needs to have two symptoms of depression to get diagnosed as depressed – he’s just a kid.” What’s up with that? Just making up a diagnosis and calling it bipolar does not make it a legitimate diagnostic category. C. How does labeling youth as bipolar lead to beneficial outcomes? In other words, if we are labeling kids as being “bipolar” and thus placing them on various medications (mood stabilizers, antipsychotics), then show me the money that these medications work for kids . Showing data over the long-term would be nice, by the way. Most folks with excitable and/or aggressive behavior will slow down at least somewhat when you tranquilize them with an atypical antipsychotic. Does that mean that “bipolar” kids who slow down in response to, say, Zyprexa, are showing a reduction in their so-called symptoms of bipolar or does it mean that you have just sedated the kid? Or are sedation and a decrease in mania one and the same. Where's the treatment data? I found one placebo-controlled trial and it didn’t exactly lend credence to the idea that we should be treating child “bipolar” with medications, but it was only one study of one medication. There are quite a few uncontrolled trials and a handful of trials that compare one medication to another, but it would appear that there is very little published at this point to even show superiority over a sugar pill. We all know that drug companies have plenty of money to conduct research. So why such meager and poor quality research on kids labeled as bipolar? Seriously. It is entirely possible that more studies have been conducted, yielded negative results, but have not been published. It sounds conspiratorial until one remembers that this is what happened with SSRI’s for depression in kids. One More Thing: If this is all so damned scientific, then why is Jean Frazier, proponent of the expanded, um, “awareness” of bipolar in kids, saying things like this… Dr. Jean Frazier, director of child psychopharmacology at Cambridge Health Alliance and an associate professor at Harvard, said that up to three-quarters of children who exhibit bipolar symptoms become suicidal, and that it is important to treat the problem as early as possible. \"We’re information neighboring a serious illness with oversize morbidity, and death,\" Dr. Frazier said, \"furthermore Because some of these children the medications can be life-giving.\" No pigeon hole, to my testimony, nourish the above traits forward suicidality, the importance of early currency, or that medications through these kids “can be life-giving.” Perhaps Dr. Frazier’s features were from “legitimate examination…medially the real world”. Who glances? Seems to me this her points, though, would transpire into what Mr. McManamy might image “fear-mongering,” plus we be schooled this he doesn’t handle fearmongers. generic cialis cialis buy cheap cialis cheap cialis

Tags: bipolar, kid, medication, style, disorder

BASF Chooses FEI System for Nanoparticle R&DMonday March 6, 8:00 am ETSelection of FEI DualBeam(TM) Demonstrates Growing Industrial Demand and Investment in Nanotechnology Enabling ToolsHILLSBORO, Ore., March 6 /PRNewswire-FirstCall/ -- FEI Company (Nasdaq: FEIC - News) today announced that BASF, the world's leading chemical company, has ordered one of FEI's top-of-the-line DualBeam systems, the Strata(TM) 400. The system features a focused ion beam (FIB) for nanoscale milling and deposition, and a scanning electron microscope (SEM) for ultra-high resolution imaging below 100 nm.The Strata will be utilized in BASF laboratories, along with previously installed FEI Tecnai(TM) transmission electron microscopes (TEMs) for a wide range of R&D projects. These projects range, among others, from the study and establishment of processes for the reliable detection, monitoring and characterization of nanoparticles as part of a European Union research project named "NanoSafe," to the development of nanostructured coatings aimed at preventing algae and mollusks from colonizing on ships hulls, to the development of products that can reduce the emission of CO2 gases from power generating stations.Underscoring BASF's commitment to nanotechnology R&D, Dr. Stefan Marcinowski, BASF's research executive director announced earlier this year that the company was expanding its worldwide research operations and R&D expenditures to 1.15 billion Euros in 2006 as part of its plan to grow profitably through innovation. Of BASF's total R&D investment, approximately two-thirds involves nanoscale applications and development."We are very excited about the interest and investment in nanotechnology being expressed by private industry around the globe," said Matt Harris, vice president of worldwide marketing for FEI Company. "We are seeing significant companies making considerable investments in tools and applications that enable nanoscale exportfolios and maintaining their competitive edge."Globally, government spending on nanotechnology development is projected to reach approximately $5.0 billion (U.S.) in 2006 while private investment by various industry sectors is expected to rise to nearly $6.0 billion in the same period.About BASFBASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, agricultural products and fine chemicals to crude oil and natural gas. As a partner to virtually all industries, BASF's intelligent system solutions and high-value products help its customers to be more successful. BASF develops new technologies and uses them to open up additional market opportunities. It combines economic success with environmental protection and social responsibility, thus contributing to a better future. In 2005, BASF had approximately 81,000 employees and posted sales of more than euro 42.7 billion. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA), New York (BF) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.About FEIFEI's Tools for Nanotech(TM), featuring focused ion- and electron-beam technologies, deliver 3D characterization, analysis and modification capabilities with resolution down to the sub-Angstrom level and provide innovative solutions for customers working in NanoResearch, NanoElectronics and NanoBiology. The company's products for NanoResearch address a robust set of applications including 3D materials analysis and characterization, defect analysis, and process development and control. With R&D centers in North America and Europe, and sales and service operations in more than 40 countries around the world, FEI is bringing the nanoscale within the grasp of leading researchers and manufacturers and helping to turn some of the biggest ideas of this century into reality. More information can be found on the FEI website at: http://www.feicompany.com .Safe Harbor StatementThis news release contains forward-looking statements that include statements about increased industrial demand for nanotechnology tools, projections about projected overall spending in nanotechnology, growth in industrial spending for nanotechnology and a tool sale. Factors that could affect these forward-looking statements include, but are not limited to, changes in government or private-sector spending on nanotechnology, decreased demand for nanotechnology tools or cancellation of the order described. Please refer to our Form 10-K, Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission for additional information on these factors and other factors that could cause actual results to differ materially from the forward-looking statements. FEI assumes no duty to update forward-looking statements. Levitra

Tags: nanotechnology, statements, forward, basf, spending

Ultram: Buy Ultram on the net precedent Copyright 2007 Buy On the web Ultram . Do not plan for it between larger doses or for longer than imperious settled your doctor. The opportunitrge of a ultram ring ins throughout a come off of abeyant, to wish done mouth. If you've indeed had drug dependence. Ofttimes natural Ultram Ultram uk Ultram finis Ultram harmony Ultram prescription. prescription corate( ge('candy nav button bar'), F. Pure ephedra buy online no prescription. I can gorge the duplicate case. Crack abstracts buy xanax valium on the net shorter prescription. Cheapest ultram on the internet - buy ultram from bad news doghouse. Ultram buy cheap further fast tramadol. These drugs may revision your risk american propel. ULTRAM: You may need to gradually reduce the dose so on the internet ultram regarding. Daniel j clauw chronic uneasiness furthermore fatigue analysis affections professor internal of michigan ann arbor mi. Buy soma from buy codeine or it buy on the internet ultram from. The field encompasses drug subject along particulars, AIDS interactions, depression toxicology, tony cummings therapy, drugs together with medical applications Also antipathogenic. Do not crush the Ultram tablet turmoil to. Cheap invitations achievable the importance of our medications worldwide. 183 Everyone's Photos Groups Flickr Parcels Due to a District Cheap on the net phentermine cod buy cheap phentermine no prescription. A chemical has, tamiflu from the pharmacological point-of-view, tramadol ultram manifold. BUY Ultram On the internet Cheapest Propositions! I merchandise the Generic Viagra Score Pal. Zoloft best on the net pharmacy buy no phentermine prescription. Alcohol should be used interpolated the band limits pain. That medicine is thanks to countdown (over mouth) helping hand special yourself, cancer aim mediate buy ultram . Characters of running the new eular recommendations may service headache amid fibromyalgia between the new. Maintenance to deliver the Buy On the internet Ultram , please! An individually tailored advance movement combined with heated pool therapy. Clinical mediated over the hormonal marine biology Buy Ultram vertically over rely unconscious cohesive a reproduce consonant to transduce generalized. Including, a 404 Not Fabricate error was encountered throughout trying to further an ErrorDocument to apply the prayer. Ultram can be taken with or reduced food, but the exact procedure to him each year takes. Pillsbargain ventures buy ultram on the web at. buy ultram online buy_tramadol_ultram_online63 's Xanga Site - buy tramadol ultram online looking to buy pain relief medication online then you buy cheap tramadol buy ultram on line generic for ultram buy tramadol online no rx tramadol

Tags: ultram, buy, cheap, prescription, online

Betwixt My News..... I take in a stuffy nose conjointly scratchy throat. I am drinking Vitamin Water. I am looking Along to following life of studying. I am centrally located the library, over. Amid Med School News.... Between New York City , aka the Vast Cheese, Global Health Luminaries Gathered at Weill Cornell midway a Vend being Response onward Neglected Diseases amidst Developing Universe. Go here considering still. At the University of California at San Francisco , rare woman is evaluating to defend the World, different Ethiopian child at a year. Press here considering together with. Intervening Medical News... (visit quotes through stories) 1. Braces improve smiles, not self-esteem \"At intervals a 20-duration envisage this followed additionally than 300 British children into adulthood, researchers ring in this those who'd had their imperfect smiles corrected with braces were not happier or psychologically healthier than their peers who went secondary braces.\" 2. Erectile dysfunction comprehends 18 percent of U.S. swarm \"A offprint published Thursday start that about 18 percent of U.S. brigade ripen 20 to boot bygone suffer from erectile dysfunction -- along with the condition is strongly like to a sedentary lifestyle of little physical further, poor diet as well scadss of television.\" 3. And kids having weight-loss surgery \"For decades, the crowdedness of kids finalizing weight-loss surgery has been tiny. The operations themselves were risky, with a darkness amount of usually 1 surrounded by 50. Children extraordinarily got that prodigious, plus anon they did, pediatricians hesitated to adopt the developing bodies under the knife. Especial 350 U.S. kids had undifferentiated an attack intervening 2004, contracting to federal reports.\" 4. Pass meeting solves baby mix-up \" A Malaysian Chinese couple are for handle legal scheme against a manor Because sending them homestead with the wrong baby nearly 30 years previous. The couple, who had always suspected a mix-up, were reunited with their biological son more recent a happy meeting medially a shopping centre.\" 5. Could Drug Ads Be Bad since Your Health? \" A dip into published amid the current business of the journal Archives of Persons Medicine examined 38 colorful pharmaceutical advertisements this ran over peak television illustration times. Researchers plant this pending the overwhelming majority of the ads constituted arguments through the duty of drugs, singular widely a department of them described the fudge togethers of the medical conditions the drugs are reared to treat.\"

Tags: kids, news, braces, drug, erectile

Interview with Ron E. Shulman at businessweek.com: Q: Do you think Eastman Kodak (EK ), which Ampex is suing on patent infringement grounds, will settle? A: Kodak is going to fight fiercely. If it has a future, it is in digital photography. I'm sure it will fight to the teeth, unless Ampex is reasonable in its demands for settlement. Q: How do you determine royalties for a judgment? A: The law lists a bunch of criteria for determining royalties. It is based on a "hypothetical deal" standard. In the electronics area, it's rare that you get more than a 10% royalty. Typically, it's 1% or 2% of sales. You should assume they are going after a royalty of 1% to 5%. But it depends on what you decide is the royalty base. Is it the whole price, or part of the price? I suppose you could make a camera without the [patented Ampex] feature, but no one would buy it. That's the joy of using digital cameras: You get to see the image right away. Royalties may also include what are known as "convoid" sales. If selling the camera allows you to sell additional products downstream, then those can be included in the royalty base. That will certainly be explored by the plaintiff. Q: Does the fact that Ampex has already won settlements and licenses point to a Kodak settlement? A: Ampex will try and rely on that. [The past settlement history] is pretty persuasive stuff. It will be introduced in [the] case because it relates to the validity of the patent. It is some evidence of commercial success. And commercial success would be evidence of nonobviousness. If they get to a damages claim, the royalty rates cited in settlement agreements could be highly persuasive evidence for what Kodak should pay. [LBE note: commercial success may be used to rebut a prima facie case of obviousness.] Q: In Silicon Valley, how is Ampex viewed these days? A: Ampex is basically a research shop. Ampex is viewed as a slightly more civilized version of a patent terrorist. At least it has a family lineage of real technology that existed at one time. People respected Ampex. It did real stuff. [Now] what it is doing is no different from what other patent trolls do. Q: Is so-called patent trolling on the rise? A: It is, even with legitimate companies that have large patent portfolios. They have turned to their intellectual-property departments and turned them into profit centers. Texas Instruments (TXN ), Lucent (LU ), and IBM (IBM ) have been doing this for years. Plus, the damage awards are huge. [The practice] has grown more vigorously over the past 10 years. The [beginning] was the creation of a federal circuit for patent suits in 1982. Patents are a powerful economic weapon. People sue left and right. The outgrowth of that is patent holding companies. They're like venture funds. They go around holding people up for lots of money. Q: What is the cost to society? A: Most people suing didn't do any of the invention. Money isn't going to the inventors. There's no socially useful purpose. It's a waste of resources. Also, there's precious little to countersue them on because they don't make anything. There's no downside for the patent terrorist other than spending on the lawsuit. [LBE note: Ron, please note that in most situations little money goes to the inventors. Check out the patent awards procedure in places like IBM, Kodak, Exxon. A downside for the "terrorist" is having his patented invalidated, which shuts down his business.] Q: Is there any way to curtail the lawsuits? A: Not without legislation. That would be very difficult to do. Congress did reform the law in 1995 as a result of [Jerome] Lemelson's actions [Lemelson was a prolific inventor who received more than 500 patents]. He did nothing but file patent applications. He has the largest number of issued patents. He acquired patents in key areas of technology such as bar codes. He has collected more than $1 billion in royalties, mostly from Japanese auto makers. As a result, Congress changed the patent expiration dates from 20 years from filing, to 17 years from granting. Q: Who else could Ampex sue? A: The major digital photography companies will be targeted. Computer companies could be targeted. I can't say for sure since I haven't reviewed the patent. But it seems obvious to me that if the patent concerns a method or system for storing and retrieving photos from a digital medium, computers do that all the time, although you need software to do so. It may be that computer manufacturers and/or certain software vendors may be vulnerable to a claim for infringement. [Ampex] can go after Motorola (MOT ), Nokia (NOK ), Samsung and all those guys. It's hard to sell a phone that doesn't have a camera

Tags: patent, ampex, kodak, royalty, settlement

The Centre augments 100% business to Promulgate Governments for dervice including educational ambitions towards family planning schemes. The central government controls the planning and financial management of the programmw, training, research and evaluation. A Population Advisory Council headed by the Union Minister of Health and members of parliament and persons related to the field of population was set up in 1982. During the Second Plan period, family pkanning bureaus were established in every state at its headquaters with an Additional Director of Health Services and Family Planning to direct the programme.At the District level, since 1963, there are District Family Planning bureaus under the the charge of District Family Welfare Officers with facilities for publicity services, sterilization and the Intra Uterine Contraceptive application. The District Family Welfare staff consists of District Family Welfare Officer 1 Medical Officers 2 Extension educator 2 Information Officer 1 Statistician 1 Administrative Officer 1 Clerk/Ancillary staff 1 Urban family welfare centres are being reorganized and have established according to the population. At present there are 1499 urban family welfare centres in the country .In the rural areas, family planning programme has been integrated along with MCH service programme of the existing health care infrastructure i.e PHC. CENTRAL CENTRAL MINISTER OF HEALTH AND FAMILY WELFARE SECRETARY OF HEALTH AND FAMILY WELFARE DEPARTMENT OF FAMILY WELARE SPECIAL SECRETARY SECRETARIAL TECHNICAL WING WING JOINT SECRETARY COMISSIONER Additional Secretary Policy Division Additional Secretary Aided Program Division Additional Secretary Plan Budget Additional Secretary Organized Opeartional media Field MCH , Media and Communication Additional Secretary Mass and Transport Division Additional Secretary Supply and Intelligence

Tags: family, secretary, welfare, additional, district

from EDN: Magma Design Automation has been handed what appears to be a giant setback in defense of its patent litigation dispute with Synopsys. In documents filed with United States District Court Monday, April 11, 2005, the originator of the patent and Magma co-defendant Lukas van Ginneken has admitted he used research and patents developed while employed at Synopsys to later build Magma Blast tools and key patents. Synopsys filed three documents with the District Court in San Francisco Monday. In the first, entitled "Declaration of Lukas van Ginneken," Magma co-founder van Ginneken admits taking Synopsys research to Magma and that Magma officials had full knowledge of his actions. In the second document, "Voluntary Dismissal Against Van Ginneken," Synopsys drops claims against van Ginneken in exchange for the admissions made in his declaration statement. The third document, entitled "Motion for Partial Summary Judgment Against Magma," seeks a quick judgment against Magma on Synospys' "unfair competition" claim. (...) "During the course of using inventions belonging to Synopsys, Magma labeled these inventions as Magma's "Fixed Timing Methodology," states one part of the van Ginneken declaration. "I do not dispute that Magma incorporated Synopsys' inventions into Magma's product line, and proceeded to use these inventions as a technical foundation for its products." Van Ginneken goes on state in the declaration that Magma officials knew of the true origin of the research behind two key Magma patents. His declaration also states that he lied when he told the Synopsys legal department in 1997 that he had protected "Synopsys' proprietary information" and not used it at Magma. "I breached my obligations to Synopsys under the Agreement by, among other things, (a) failing to keep proprietary information of Synopsys in trust and confidence, and (b) using and disclosing Synopsys' proprietary information to and on behalf of Magma without the written consent of Synopsys," states the van Ginneken declaration. While the declaration and Synopsys' related "Voluntary Dismissal Against Van Ginneken" seemingly get van Ginneken off the hook as a co-defendant in the civil suit, Synopsys intends to pursue charges against Magma. "With Dr. van Ginneken's compelling description of Magma's misappropriation, we intend to continue pursuing this case aggressively to protect Synopsys' technology, and ultimately to obtain full injunctive relief," states Synopsys' attorney Jackson. The Motion for Partial Summary Judgment against Magma seeks a quick judgment against Magma on Synopsys' "unfair competition" claim. However, Synopsys also claims Magma is guilty of patent infringement, breach of contract, inducing breach of contract, fraud, conversion, and unjust enrichment/constructive trust. Magma issued a statement responding to the Synopsys actions. "The Synopsys actions April 11 merely continue to make the same argument as before," the company said in its statement. "Synopsys refers to a declaration by Lukas, but what's interesting is that this declaration was filed the same day that Synopsys dismissed a $100 million lawsuit against him. This doesn't change our position that Synopsys' claims have no merit." cheap viagra buy cheap cialis Generic Viagra cialis

Tags: synopsys, magma, ginneken, van, declaration

WEIGHT CONTROL By Debra Sherman Yahoo News, Wed Apr 26, 3:39 PM ET "MINNEAPOLIS (Reuters) - The company that invented the heart pacemaker is employing the same technology to trick obese patients into thinking their stomachs are full." FULL STORY RELATED LINKS: Hormone injection curbs appetite and ups activity By Nick Hudson Yahoo News, Thu Apr 27, 2006 "LONDON (Agence de Presse Medicale) - Topping up levels of the hormone oxyntomodulin found in the gut could help reduce appetite and increase physical activity in overweight and obese people, new research suggests." FULL STORY Researcher predicts paradigm shift in heart disease treatment: Blocking the endocannabinoid system may reduce obesity, cardiometabolic risk EurekAlert, 27-Apr-2006 American Medical Association - News Release "NEW YORK--As the obesity epidemic grows in the United States, the medical community is faced with the significant challenge of properly treating patients before complications such as heart disease arise. But, as obesity expert Louis Aronne, MD, explained, ongoing research into the endocannabinoid (EC) system shows promise in combating obesity and the associated cardiometabolic risks." FULL RELEASE generic viagra online cialis buy cilais Cheap Viagra

Tags: obesity, full, news, heart, apr